Paladin Labs, Inc.
https://www.paladin-labs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Paladin Labs, Inc.
France: A European Leader In Rare Diseases
France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.
Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
Deal Watch: Bayer Ties Up With Twist On Optimization Of Antibody Discovery
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Allon Therapeutics, Inc.
- Ativa Pharma S.A,
- Labopharm Inc.
- ViRexx Medical Corp.
- Triton Pharma Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice